Revolutionizing Healthcare
Through Mitochondrial Innovation

We develop next-generation mitochondrial therapeutics to treat rare diseases and cancer—bridging science, innovation, and impact!

ABOUT US

PAEAN Biotechnology a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to Treat Diseases.

3 Products

Under Development

Managed by a Professional Team Over 20 Years of Experience in Digital Biotechnology

$21M+

R&D and Investment Funds Raised Towards Development & Commercialization of the World's First Mitochondrial Therapy

OUR MISSION

Our mission is to revolutionize healthcare
by harnessing the untapped potential of mitochondria.

We are committed to advancing mitochondria-based technologies to develop innovative therapies for rare, chronic, and hard-to-treat diseases—improving quality of life through science-driven breakthroughs.

OUR VALUES

At PAEAN, we are driven by values that shape our science and spirit.

We foster innovation to push the boundaries of biotechnology, embrace collaboration to work across disciplines and partners, harness advanced technology to solve unmet medical needs, and uphold rigor in every process to ensure excellence and trust.

These values are embedded in everything we do—every discovery, every trial, every breakthrough.

Innovative

Collaborative

Technology

Rigorous

THE UNDERSTANDING

The Power of Mitochondria, Are present in every human cell.

They not only generate energy but also play an important role in cell proliferation, signaling, etc.

Mitochondria have unique characteristics that can be delivered into cells through endocytosis. With PAEAN's mitochondria-based therapeutics, we transform mitochondria into powerful biopharmaceutical agents to address critical medical needs.

OUR TECHNOLOGIES

Applying the unique characteristics of mitochondria and proprietary technology platform, PAEAN is developing a first-in-class mitochondria-based pharmaceutical product that has a large potential to treat various rare diseases and cancer.

MitoTherapy Product
Mitochondrial Transplatation

MitoTherapy Products are novel medicinal products using mitochondria isolated from human stem cells or human blood. Mitochondria are unique organelles that are responsible for energy production in cells. Based on our experimental results, mitochondria have a high potential to treat inflammatory diseases.

Mitoceutical Product
Modified Mitochondrial Transplatation

Mitoaugmentation Product
Mitochondria-augmented
Cell Therapy

THE PIPELINE

PAEAN’s Pipeline reflects our strategic focus on high-burden diseases with limited treatment options, progressing toward regulatory milestones with the support of national and global funding partners.

Platform	Pipeline	Indication
Mitochondrial Transplantation (MitoTherapy Product)	PN-101	PM/DM
	PN-RS	Parkinson Disease
	PN-RS	Hearing Loss
	PN-RS	Ophthalmic Disease
Modified Mitochondrial Transplantation (MitoCeutical Product)	PN-30X	Cancer, CNS Diseases
Mitochondrial Augmentation Cell Therapy (Mitoaugmentation Product)	PN-20X	TBD

MILESTONE

Milestones That Shape Our Journey, From scientific
breakthroughs to clinical progress, we build step by step.

Research Collaboration

Seoul National University Hospital

2018
Until Now

Pre-series A Funding

Korea Investment Partners with KRW 1.5 B

JUN 2018

Series A Funding

Korea Investment Partners, Hana Ventures, Timefolio with KRW 6 B

Jun 2019

Bridge Funding

Korea Investment Partners, Hana Ventures Timefolio with KRW 4.5 B

JUN 2021

Mitochondria GMP Facility

Jung-gu, Seoul

JUN 2021